IBA and RaySearch expand their partnership in proton therapy
26 Oktober 2021 - 5:10PM
IBA and RaySearch expand their partnership in proton therapy
RaySearch Laboratories AB (publ) and IBA announce
that they expanded their partnership in proton therapy within the
areas of flash radiotherapy, proton ARC therapy, and treatment of
moving tumors.
Louvain-La-Neuve, Belgium, 26 October
2021 – IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology, today announces
RaySearch Laboratories AB (publ) and IBA expand their partnership
in proton therapy within the areas of flash radiotherapy, proton
ARC therapy, and treatment of moving tumors
IBA and RaySearch have had a strategic
partnership on a global level since 2013. Over the years the
collaboration has deepened and the combination of RayStation® and
IBA’s Proteus® systems are nowadays a well proven and de facto
industry standard. As of today, the majority of IBA’s Proteus®
centers have selected RayStation® as treatment planning system and
in total 27 centers around the world are equipped with a Proteus®
proton delivery system in combination with RayStation®.
As part of the collaboration, RayCare® oncology
information system from RaySearch, will be customized for optimal
use together with the IBA delivery solutions. In both RayStation®
and RayCare®, as well as in the IBA delivery solutions, joint
features, dedicated software interfaces and modified graphical user
interface components will allow for a close and seamless workflow
integration with optimized performance. The result will be a
turnkey solution for all software and hardware needed to deliver
outstanding proton therapy treatments.
The extended collaboration includes the
following areas:
- DynamicARC®1 for Proton ARC therapy
planning in RayStation®: The next
evolution in proton delivery, promising easy delivery scheme,
decreased delivery times, and improved dose conformality.
- Treatment planning in
RayStation® in
ConformalFLASH®2: Combines the benefits of FLASH
radiotherapy with the dosimetric benefits of proton radiationand
the Bragg Peak. FLASH radiotherapy has the potential to
revolutionize the future of cancer treatment by delivering
ultra-high dose rate radiation, several orders of magnitude higher
than what is currently used in conventional clinical
radiotherapy.
- Machine specific treatment planning tools for moving
tumors: Enables to master and guarantee the dose
conformality along the treatment course for patients with moving
tumors by exploiting the machine characteristics to its full
potential and providing dedicated imaging processing
capabilities.
Olivier Legrain, CEO of IBA,
says: “We continue to demonstrate year after year that our
combined expertise is providing superior integrated proton therapy
solutions for the benefits of clinicians allowing them to take best
care of their patients.”
Johan Löf, founder and CEO, RaySearch,
says: “Today the combination of RaySearch’s RayStation®
and IBA’s Proteus® is an industry standard within proton therapy.
With the now announced expanded partnership between our companies,
we aim to take proton therapy to the next level by developing
several innovative radiotherapy technologies that will
significantly improve patient care.”
***ENDS***
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,500 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com.
About RaySearch
RaySearch is a medical technology company that
develops innovative software solutions to improve cancer care. The
company markets worldwide its treatment planning system RayStation®
and next-generation oncology information system RayCare®*. The
latest additions to RaySearch's product line are RayIntelligence®
and RayCommand®. RayIntelligence® is an oncology analysis system
(OAS) that cancer clinics can use to collect, structure, and
analyze data. The treatment control system (TCS) RayCommand® is
designed as a link between the treatment machine and the systems
for dose planning and oncology information. RaySearch software is
used in about 2,600 clinics in over 65 countries. The company was
founded in 2000 and the share has been listed on Nasdaq Stockholm
since 2003. More information about RaySearch is available at
raysearchlabs.com
About RayStation®
RayStation® is a flexible, innovative treatment
planning system, chosen by many of the leading cancer centers
worldwide. It combines unique features such as unmatched adaptive
therapy capabilities, multi-criteria optimization, market-leading
algorithms for treatment plan optimization for HDR brachytherapy
and external beam therapy photons, electrons, and protons, as well
as helium and carbon ions. RayStation® supports a wide range of
treatment machines, providing one control center for all treatment
planning needs and ensuring centers get greater value from existing
equipment. RayStation® also seamlessly integrates with RayCare®. By
harmonizing the treatment planning, we enable better care for
cancer patients worldwide.
About RayCare®The RayCare® oncology information
system (OIS) is designed to support the many complex logistical
challenges faced by today’s oncology clinics. RayCare® is closely
integrated with RayStation® and provides seamless access to all the
powerful planning tools in RayStation®, and RayCommand®. The system
efficiently coordinates activities in radiation therapy and offers
advanced features for clinical workflow automation, and adaptive
radiation therapy. RayCare® responds to the demand from clinics for
a more user-friendly and workflow-oriented information system that
can support the future of cancer care.
CONTACTS
IBA
Aymeric HarmantProton Therapy Marketing Global
Director+32 10 475 890global.marketing@iba-group.com
Olivier
Lechien
Corporate Communication
Director
+32 10 475
890
communication@iba-group.com
For media and investor enquiries: Consilium
Strategic Communications Amber Fennell, Angela Gray, Lucy
Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com
RaySearchJohan LöfFounder and
CEO, RaySearch Laboratories AB (publ)Telephone: +46
(0)8-510 530 00johan.lof@raysearchlabs.com
Peter ThysellCFO, RaySearch Laboratories AB
(publ) Telephone: +46 (0)70 661 05
59peter.thysell@raysearchlabs.com
* Subject to regulatory clearance in some
markets.
1 DynamicARC® is a registered brand of the IBA’s Proton Arc
therapy solution currently under development phase.
2 ConformalFLASH® is a registered brand of the IBA’s Proton
Flash therapy solution currently under research and development
phase.
- 2110126-IBA_RaySearch-ASTRO21-EN
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Apr 2023 bis Apr 2024